BioLineRx (BLRX) Beginning Cash Balance (2012 - 2026)

BioLineRx's Beginning Cash Balance history runs 13 years deep, the most recent figure standing at $10.4 million for Q1 2025.

• In Q1 2025, Beginning Cash Balance rose 145.26% year-over-year to $10.4 million; the TTM figure through Dec 2025 stood at $10.4 million (up 145.26% YoY), while the FY2025 annual figure was $10.4 million, up 145.26% from the prior year.
• Beginning Cash Balance for Q1 2025 stood at $10.4 million, up from $4.3 million in the prior quarter.
• The five-year high for Beginning Cash Balance was $16.8 million in Q1 2021, with the low at $4.3 million in Q1 2024.
• The 5-year median for Beginning Cash Balance is $10.6 million (2023), against an average of $11.0 million.
• The sharpest annual moves came in 2021 and 2024: Beginning Cash Balance surged 217.75% in 2021, then plunged 59.81% in 2024.
• BioLineRx's Beginning Cash Balance stood at $16.8 million in 2021, then slipped by 22.82% to $13.0 million in 2022, then slipped by 18.5% to $10.6 million in 2023, then sank by 59.81% to $4.3 million in 2024, then surged by 145.26% to $10.4 million in 2025.
• Business Quant data shows BLRX's Beginning Cash Balance at $10.4 million in Q1 2025, $4.3 million in Q1 2024, and $10.6 million in Q1 2023.